I was disappointed in “Blood relatives.” It ignored the pioneering work by people at the company Somatogen, now known as Baxter Hemoglobin Therapeutics. They first published work on a recombinant hemoglobin for use as a blood substitute in Nature in 1990. Later, they demonstrated definitively that many of the problems associated with blood substitutes were caused by nitric oxide scavenging and designed a recombinant hemoglobin that significantly decreased that activity.
Bruce A. Kerwin
Thousand Oaks, Calif.
From the Nature Index
Subscribers, enter your e-mail address for full access to the Science News archives and digital editions.